These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15930983)

  • 1. The pathophysiologic rationale for biological therapies in inflammatory bowel disease.
    Gordon JN; Di Sabatino A; Macdonald TT
    Curr Opin Gastroenterol; 2005 Jul; 21(4):431-7. PubMed ID: 15930983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New mediators of immunity and inflammation in inflammatory bowel disease.
    Monteleone G; Fina D; Caruso R; Pallone F
    Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune mechanisms in chronic inflammatory bowel disease.
    Braegger CP; MacDonald TT
    Ann Allergy; 1994 Feb; 72(2):135-41. PubMed ID: 8109803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune dysfunction in inflammatory bowel disease.
    Neuman MG
    Transl Res; 2007 Apr; 149(4):173-86. PubMed ID: 17383591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms.
    Dignass AU; Baumgart DC; Sturm A
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():9-17. PubMed ID: 15352888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency.
    Mannon PJ; Fuss IJ; Dill S; Friend J; Groden C; Hornung R; Yang Z; Yi C; Quezado M; Brown M; Strober W
    Gastroenterology; 2006 Sep; 131(3):748-56. PubMed ID: 16952544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications.
    Amati L; Caradonna L; Jirillo E; Caccavo D
    Ital J Gastroenterol Hepatol; 1999 May; 31(4):313-25. PubMed ID: 10425578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling for inflammation and repair in inflammatory bowel disease.
    Neuman MG
    Rom J Gastroenterol; 2004 Dec; 13(4):309-16. PubMed ID: 15624029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
    Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
    Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal T cells as a target for treatment of IBD.
    Watanabe M; Yamazaki M; Kanai T
    J Gastroenterol; 2003 Mar; 38 Suppl 15():48-50. PubMed ID: 12698871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
    Neurath MF
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving knowledge and therapy of inflammatory bowel disease.
    Korzenik JR; Podolsky DK
    Nat Rev Drug Discov; 2006 Mar; 5(3):197-209. PubMed ID: 16518373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation.
    Powrie F; Leach MW
    Ther Immunol; 1995 Apr; 2(2):115-23. PubMed ID: 8729882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene transfer approaches for the treatment of inflammatory bowel disease.
    Wirtz S; Neurath MF
    Gene Ther; 2003 May; 10(10):854-60. PubMed ID: 12732871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
    Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
    Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the novel Th17 cytokine IL-26 in intestinal inflammation.
    Dambacher J; Beigel F; Zitzmann K; De Toni EN; Göke B; Diepolder HM; Auernhammer CJ; Brand S
    Gut; 2009 Sep; 58(9):1207-17. PubMed ID: 18483078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease.
    Podolsky DK
    Dig Dis; 2009; 27(3):366-9. PubMed ID: 19786766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.